1
|
Zheng S, Rammohan N, Sita T, Teo PT, Wu Y, Lesniak M, Sachdev S, Thomas TO. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning. Sci Rep 2024; 14:2126. [PMID: 38267516 PMCID: PMC10808248 DOI: 10.1038/s41598-024-51765-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 01/09/2024] [Indexed: 01/26/2024] Open
Abstract
Identification of isocitrate dehydrogenase (IDH)-mutant glioma patients at high risk of early progression is critical for radiotherapy treatment planning. Currently tools to stratify risk of early progression are lacking. We sought to identify a combination of molecular markers that could be used to identify patients who may have a greater need for adjuvant radiation therapy machine learning technology. 507 WHO Grade 2 and 3 glioma cases from The Cancer Genome Atlas, and 1309 cases from AACR GENIE v13.0 datasets were studied for genetic disparities between IDH1-wildtype and IDH1-mutant cohorts, and between different age groups. Genetic features such as mutations and copy number variations (CNVs) correlated with IDH1 mutation status were selected as potential inputs to train artificial neural networks (ANNs) to predict IDH1 mutation status. Grade 2 and 3 glioma cases from the Memorial Sloan Kettering dataset (n = 404) and Grade 3 glioma cases with subtotal resection (STR) from Northwestern University (NU) (n = 21) were used to further evaluate the best performing ANN model as independent datasets. IDH1 mutation is associated with decreased CNVs of EGFR (21% vs. 3%), CDKN2A (20% vs. 6%), PTEN (14% vs. 1.7%), and increased percentage of mutations for TP53 (15% vs. 63%), and ATRX (10% vs. 54%), which were all statistically significant (p < 0.001). Age > 40 was unable to identify high-risk IDH1-mutant with early progression. A glioma early progression risk prediction (GlioPredictor) score generated from the best performing ANN model (6/6/6/6/2/1) with 6 inputs, including CNVs of EGFR, PTEN and CDKN2A, mutation status of TP53 and ATRX, patient's age can predict IDH1 mutation status with over 90% accuracy. The GlioPredictor score identified a subgroup of high-risk IDH1-mutant in TCGA and NU datasets with early disease progression (p = 0.0019, 0.0238, respectively). The GlioPredictor that integrates age at diagnosis, CNVs of EGFR, CDKN2A, PTEN and mutation status of TP53, and ATRX can identify a small cohort of IDH-mutant with high risk of early progression. The current version of GlioPredictor mainly incorporated clinically often tested genetic biomarkers. Considering complexity of clinical and genetic features that correlate with glioma progression, future derivatives of GlioPredictor incorporating more inputs can be a potential supplement for adjuvant radiotherapy patient selection of IDH-mutant glioma patients.
Collapse
Affiliation(s)
- Shuhua Zheng
- Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
| | - Nikhil Rammohan
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Timothy Sita
- Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - P Troy Teo
- Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Yilin Wu
- Department of Mathematics, DigiPen Institute of Technology, Redmond, WA, USA
| | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Sean Sachdev
- Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Tarita O Thomas
- Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Radiation Oncology, Northwestern Medical Group, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, USA.
| |
Collapse
|
2
|
Khan F, Lin Y, Ali H, Pang L, Dunterman M, Hsu WH, Frenis K, Rowe RG, Wainwright D, McCortney K, Billingham L, Miska J, Horbinski C, Lesniak M, Chen P. LDHA-regulated tumor-macrophage symbiosis promotes glioblastoma progression. Res Sq 2023:rs.3.rs-3401154. [PMID: 37886538 PMCID: PMC10602051 DOI: 10.21203/rs.3.rs-3401154/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2023]
Abstract
Abundant macrophage infiltration and altered tumor metabolism are two key hallmarks of glioblastoma. By screening a cluster of metabolic small-molecule compounds, we show that inhibiting glioblastoma cell glycolysis impairs macrophage migration and lactate dehydrogenase (LDH) inhibitor stiripentol (an FDA-approved anti-seizure drug for Dravet Syndrome) emerges as the top hit. Combined profiling and functional studies demonstrate that LDHA-directed ERK pathway activates YAP1/STAT3 transcriptional co-activators in glioblastoma cells to upregulate CCL2 and CCL7, which recruit macrophages into the tumor microenvironment. Reciprocally, infiltrating macrophages produce LDHA-containing extracellular vesicles to promote glioblastoma cell glycolysis, proliferation, and survival. Genetic and pharmacological inhibition of LDHA-mediated tumor-macrophage symbiosis markedly suppresses tumor progression and macrophage infiltration in glioblastoma mouse models. Analysis of tumor and plasma samples of glioblastoma patients confirms that LDHA and its downstream signals are potential biomarkers correlating positively with macrophage density. Thus, LDHA-mediated tumor-macrophage symbiosis provides therapeutic targets for glioblastoma.
Collapse
Affiliation(s)
| | - Yiyu Lin
- Department of Genetics, The University of Texas MD Anderson Cancer Center
| | - Heba Ali
- Department of Genetics, The University of Texas MD Anderson Cancer Center
| | - Lizhi Pang
- Feinberg School of Medicine, Northwestern University
| | | | - Wen-Hao Hsu
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Sullivan J, Chandler J, Lesniak M, Tate M, Sonabend A, Kalapurakal J, Horbinski C, Lukas R, Kumthekar P, Sachdev S. Clinical outcomes for pleomorphic xanthoastrocytoma patients: an institutional experience. Res Sq 2023:rs.3.rs-2535551. [PMID: 36778274 PMCID: PMC9915763 DOI: 10.21203/rs.3.rs-2535551/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Purpose Report our institutional experience with pleomorphic xanthoastrocytoma (PXA) to contribute to limited data on optimal management. Methods Patients with pathologically confirmed PXA treated at our institution between 1990 and 2019 were identified. Demographic information, tumor grade, treatment variables, and clinical outcomes were collected from patient charts. Kaplan-Meier estimates were used to summarize two primary outcome measurements: progression-free survival (PFS) and overall survival (OS). Outcomes were stratified by tumor grade and extent of resection. Cox regression and log-rank testing were performed. Results We identified 17 patients with pathologically confirmed PXA. Two patients were excluded due to incomplete treatment information or < 6m of follow-up; 15 patients were analyzed (median follow-up 4.4y). Six patients had grade 2 PXA and 9 had grade 3 anaplastic PXA. The 2-year and 5-year PFS for the cohort was 57% and 33%, respectively; 2-year and 5-year OS was 93% and 75%, respectively. Patients with grade 2 tumors exhibited superior PFS compared to those with grade 3 tumors (2-year PFS: 100% vs. 28%, 5-year PFS: 60% vs. 14%), hazard ratio, 5.09 (95% CI:1.06-24.50), p = 0.02. Undergoing a GTR also yielded improved outcomes (hazard ratio: 0.38, p = 0.15). All but one (89%) of the grade 3 patients underwent RT. Conclusion The poor survival of the cohort, especially with grade 3 tumors, suggests the need for more aggressive treatment, including maximal resection followed by intensive adjuvant therapy. Better prognostics of tumor recurrence are needed to guide the use of adjuvant therapy.
Collapse
Affiliation(s)
| | - James Chandler
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Maciej Lesniak
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Matthew Tate
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Adam Sonabend
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - John Kalapurakal
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Craig Horbinski
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Rimas Lukas
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Priya Kumthekar
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| | - Sean Sachdev
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
| |
Collapse
|
4
|
Hou D, Castro B, Dapash M, Zolp A, Katz J, Arrieta V, Biermann J, Melms J, Kueckelhaus J, Benotmane J, Youngblood M, Rashidi A, Billingham L, Dmello C, Vazquez-Cervantes G, Lopez-Rosas A, Han Y, Patel R, Chia TY, Sun L, Prins R, Izar B, Heiland DH, Zhang P, Sonabend A, Miska J, Lesniak M, Zhao J, Lee-Chang C. B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression. Res Sq 2023:rs.3.rs-2399170. [PMID: 36711497 PMCID: PMC9882679 DOI: 10.21203/rs.3.rs-2399170/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Immunotherapy has revolutionized cancer treatment but has yet to be translated into brain tumors. Studies in other solid tumors suggest a central role of B-cell immunity in driving immune-checkpoint-blockade efficacy. Using single-cell and single-nuclei transcriptomics of human glioblastoma and melanoma brain metastasis, we found that tumor-associated B-cells have high expression of checkpoint molecules, known to block B-cell-receptor downstream effector function such as plasmablast differentiation and antigen-presentation. We also identified TGFβ-1/TGFβ receptor-2 interaction as a crucial modulator of B-cell suppression. Treatment of glioblastoma patients with pembrolizumab induced expression of B-cell checkpoint molecules and TGFβ-receptor-2. Abrogation of TGFβ using different conditional knockouts expanded germinal-center-like intratumoral B-cells, enhancing immune-checkpoint-blockade efficacy. Finally, blocking αVβ8 integrin (which controls the release of active TGFβ) and PD-1 significantly increased B-cell-dependent animal survival and immunological memory. Our study highlights the importance of intratumoral B-cell immunity and a remodeled approach to boost the effects of immunotherapy against brain tumors.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jason Miska
- University of Miami Miller School of Medicine
| | | | | | | |
Collapse
|
5
|
Castro B, Fischietti M, Zolp A, Zhao J, Hou D, Nguyen L, Wan H, Zhang P, Han Y, Lopez-Rosas A, Platanias L, Stupp R, Miska J, Lesniak M, Lee-Chang C. EXTH-52. HARNESSING A B CELL THERAPY TO PROMOTE ANTI-GLIOBLASTOMA HUMORAL RESPONSE. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac209.850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Glioblastoma (GBM) continues to retain its dismal prognosis despite numerous new therapeutic modalities to target various aspects of the tumor. There is a need to identify new, and even personalized, targetable GBM specific antigens. Our B-cell-based vaccine (BVax) is generated by isolating immune experienced B cells, identified by 4-1BBL, from murine secondary lymphoid organs or patient blood. We have shown this subset of B cells to have anti-tumoral potential in GBM. These cells are strengthened with BAFF, CD40, and IFNg stimulation to form BVax and then activated in vitro to form plasmablasts. Immunoprecipitation-mass spectrometry is performed using BVax-derived antibodies and tumor lysate from the paired patient specimen. We have identified unique antigens bound by BVax-derived antibodies. Given the significant therapeutic benefit we have seen using BVax-derived antibodies in preclinical murine models, we hypothesize that targeting these unique antigens would have significant therapeutic benefit in GBM patients. We focused on antigens that showed a survival benefit with lower expression using CGGA database analysis. We then confirm the presence and prevalence of the antigens within tumor cells in the patient’s tissue using immunohistochemistry, identifying some antigens in up to 15% of tumor cells. Using our brain tumor bank repository, we screened other GBM patient’s tissue for the presence of these markers to determine the broader applicability of targeting each antigen. We have identified proteins key in extracellular matrix formation which promote tumor growth and progression in cancer, including the ability to induce epithelial-mesenchymal transition. Simultaneously we have developed a computational algorithm to predict which antigens BVax-derived antibodies will bind using single cell RNA sequencing data from GBM patient-derived tumor and BVax, which may have broader applicability to a larger number of patients. Both techniques serve as exciting platforms to identify new therapeutic targets in GBM.
Collapse
Affiliation(s)
- Brandyn Castro
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | | | | - Junfei Zhao
- Department of Systems Biology at Columbia University , New York, NY, 10032 , USA
| | - David Hou
- Northwestern University Feinberg School of Medicine , Chicago, IL , USA
| | | | | | - Peng Zhang
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | - Yu Han
- Northwestern University , Chicago , USA
| | | | | | - Roger Stupp
- Northwestern University — Neurological Surgery; Feinberg School of Medicine , Chicago, IL , USA
| | - Jason Miska
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | - Maciej Lesniak
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | |
Collapse
|
6
|
Zolp A, Rashidi A, Chia TY, Dmello C, Arrieta V, Zhao J, Castro B, Markwell S, Heiland DH, Brat D, Chandel N, Lesniak M, Lee-Chang C, Miska J. TMET-14. TUMOR-ASSOCIATED MYELOID CELL-DERIVED CREATINE PROMOTES GLIOBLASTOMA GROWTH IN HYPOXIC NICHES AND PSEUDOPALISADING TUMOR REGIONS. Neuro Oncol 2022. [PMCID: PMC9661033 DOI: 10.1093/neuonc/noac209.1019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Glioblastoma (GBM) consists of a unique tumor microenvironment (TME) dominated by infiltrating tumor-associated myeloid cells (TAMCs). TAMCs are central to tumor growth and understanding how they support tumor progression is critical to identifying new therapeutic modalities. Examination of the metabolic and genetic phenotypes of TAMCs revealed that the de-novo creatine phenotype is central to their identity. Immunohistochemistry and multiplex fluorescence in GBM patient-derived tissue showed TAMC infiltration localizing to hypoxic pseudopalisading regions. Furthermore, single-cell RNAseq analysis of human and mouse models of GBM identified that the transporter of creatine, Slc6a8, is located on tumor cells within these regions. Spatial transcriptomics confirmed this transporter-synthesis gene compartmentalization is specific to hypoxic pseudopalisading regions, and further elucidated a radial glial cell gene signature for tumor cells expressing Slc6a8. Murine models recapitulated the TAMC de-novo creatine metabolic phenotype both ex-vivo and in-vitro. Metabolomics showed that TAMC-derived creatine can transfer to tumor cells in-vitro and is enhanced under hypoxic conditions. β-guanidinopropionic acid (β-GPA) is a creatine analog proposed to block Slc6a8 function and effectively blocked TAMC-derived creatine transfer to tumor cells in-vitro. Furthermore, β-GPA inhibited both the viability and size of spheres for tumor cells grown in stem-cell conditions. Lastly, inhibition of creatine transport using clinically relevant inhibitors enhanced survival following tumor implantation in murine models. This work highlights the key role of creatine in the pseudopalisading and hypoxic niche in GBM, offering evidence for a potential benefit in targeting this axis for GBM therapy regimens.
Collapse
Affiliation(s)
| | | | | | | | | | - Junfei Zhao
- Department of Systems Biology at Columbia University , New York, NY, 10032 , USA
| | - Brandyn Castro
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | | | | - Daniel Brat
- Department of Pathology, Northwestern University , Chicago, IL , USA
| | | | - Maciej Lesniak
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | | - Jason Miska
- Northwestern University Feinberg School of Medicine , Chicago , USA
| |
Collapse
|
7
|
Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright D, Ahmed A, Heimberger A, Lesniak M, Chen P. TMIC-78. CIRCADIAN REGULATOR CLOCK DRIVES IMMUNOSUPPRESSION IN GLIOBLASTOMA. Neuro Oncol 2022. [PMCID: PMC9661303 DOI: 10.1093/neuonc/noac209.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
The symbiotic interactions between cancer stem cells and the tumor microenvironment (TME) are critical for tumor progression. However, the molecular mechanism underlying this symbiosis in glioblastoma (GBM) remains enigmatic. Here, we show that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 (BMAL1) in glioma stem cells (GSCs) drive immunosuppression in GBM. Integrated analyses of the data from transcriptome profiling, single-cell RNA sequencing, and TCGA datasets, coupled with functional studies, identified legumain (LGMN) as a direct transcriptional target of the CLOCK–BMAL1 complex in GSCs. Moreover, CLOCK-directed olfactomedin-like 3 (OLFML3) upregulates LGMN in GSCs via the hypoxia-inducible factor 1-alpha (HIF1A) signaling. Consequently, LGMN promotes microglial infiltration into the GBM TME via upregulating CD162, and polarizes infiltrating microglia towards an immune-suppressive phenotype. In GBM mouse models, inhibition of the CLOCK–OLFML3–HIF1A–LGMN–CD162 axis reduces intratumoral immune-suppressive microglia, increases CD8+ T cell infiltration, activation and cytotoxicity, and synergizes with anti-PD1 therapy. In human GBM, the CLOCK-regulated LGMN signaling correlates positively with microglial level and poor prognosis. Together, these findings uncover the CLOCK–OLFML3–HIF1A–LGMN axis as a molecular switch that controls microglial biology and immunosuppression, thus revealing potential new therapeutic targets for GBM patients.
Collapse
Affiliation(s)
| | - Wen-Hao Hsu
- MD Anderson Cancer Center - Department of Cancer Biology , HOUSTON, TX , USA
| | | | | | | | - Derek Wainwright
- Northwestern University, Feinberg School of Medicine , Chicago, IL , USA
| | | | | | - Maciej Lesniak
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | |
Collapse
|
8
|
Hou D, Castro B, Zolp A, Dapash M, Arrieta V, Zhao J, Zhang P, Rashidi A, Burnham E, Patel R, Lesniak M, Miska J, Lee-Chang C. TMIC-42. LEVERAGING B CELL IMMUNITY TO PROMOTE IMMUNOTHERAPY IN GLIOBLASTOMA. Neuro Oncol 2022. [PMCID: PMC9661055 DOI: 10.1093/neuonc/noac209.1086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Immunotherapy has revolutionized cancer treatment but has yet to be translated into brain tumors. Studies in melanoma and sarcoma, amongst other models, have revealed the accumulation of germinal-center-like B cells as a key survival predictor post-PD1 blockade. We seek to leverage B cell immunity to enhance immunotherapy effectiveness in glioblastoma (GBM). In human GBM and murine glioma models, we found that B cells in the tumor microenvironment (TME) are activated, but the expression of co-inhibitory molecules such as CD32 and CD72 blocks downstream effector function. Transcriptomic analysis showed high expression of inhibitory TGFβ receptors on B cells and high levels of TGFβ1 cytokine in the TME. We showed direct inhibition of B cell function through TGFβ signaling that could be prevented with TGFβ receptor blockade. Spatial multiplex immunofluorescence analysis of the TME revealed that tumor and myeloid cells express high levels of TGFβ and are also near B cells, allowing for TGFβ-mediated B cell inhibition. Blocking the TGFβ pathway via transgenic mice with TGFβ receptor knockout on B cells or TGFβ cytokine knockouts in myeloid cells, or generation of a CT2A tumor line with TGFβ cytokine knockdown, all demonstrated a survival benefit and more germinal-center-like B cells. There was also increased T cell proliferation and anti-tumor cytotoxicity. Finally, inhibiting αVβ8 integrin, a required factor that releases active TGFβ, is a translatable approach that also increased B cell proliferation and animal survival. Dual treatment with αVβ8+PD1 blockade showed the most potent survival as well as immunological memory against tumor re-challenge. Analysis of the B and T cell compartments after dual treatment showed synergy, with robust cellular proliferation and functional differentiation of plasmablasts and effector T cells. Collectively, our study highlights the importance of B cells in the TME and a remodeled approach to boost the effects of immunotherapy against GBM.
Collapse
Affiliation(s)
- David Hou
- Northwestern University Feinberg School of Medicine , Chicago, IL , USA
| | - Brandyn Castro
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | - Andrew Zolp
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | - Mark Dapash
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | | - Junfei Zhao
- Department of Systems Biology at Columbia University , New York, NY, 10032 , USA
| | - Peng Zhang
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | | | | | | - Maciej Lesniak
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | - Jason Miska
- Northwestern University Feinberg School of Medicine , Chicago , USA
| | | |
Collapse
|
9
|
Castro B, Dapash M, Hou D, Rashidi A, Kanojia D, Zhang P, Lopez-Rosas A, Han Y, Balyasnikova I, Stupp R, Miska J, Lesniak M, Chang C. IMMU-29. B-CELL-BASED VACCINE PRODUCES GLIOBLASTOMA-REACTIVE ANTIBODIES THAT CONTRIBUTE TO TUMOR CLEARANCE. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Glioblastomas (GBM) are characterized by a strong immunosuppressive environment, contributing to their poor prognosis and limited therapeutic response to immunotherapies. B-cells represent a unique opportunity to promote immunotherapy due to their potential to kill tumors by both cellular and humoral immunity. To generate our B-cell-based vaccine (BVax) platform, we activated 41BBL+ B cells from tumor bearing mice or GBM patient blood with BAFF, CD40, and IFNg. We have previously demonstrated that BVax potentiates radiation therapy, temozolomide and checkpoint blockade in murine models of GBM via enhancement of CD8+ T-cell based immunity. The aim of this current study is to evaluate the humoral effector functions of BVax. We examined the antibody (Ab) repertoire in vivo from serum of tumor-bearing B-cell knockout mice treated with BVax or by ex vivo stimulation of patient-derived BVax. Upon systemic administration, BVax infiltrates the tumor where it differentiates into plasmablasts. Murine BVax- and BNaive-derived serum immunoglobulin generated in vivo showed that the majority of murine BVax-derived Ab were IgG isotype, while BNaive mainly produced IgM isotype. Transfer of IgG from BVax treated mice directly into tumors of recipient animals significantly prolonged their survival, demonstrating anti-tumor cytotoxicity directly through humoral immunity. Patient-derived BVax activated ex vivo showed a plasmablast phenotype and the Ab repertoire supports the previous findings seen in our murine model. Our work suggests BVax-derived IgGs role in antibody-dependent cellular cytotoxicity and improved survival in murine models. This function, in addition to its role in cellular immunity against GBM, renders BVax a potentially effective alternative immunotherapeutic option for GBM patients.
Collapse
Affiliation(s)
- Brandyn Castro
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | - David Hou
- Northwestern University, Chicago, USA
| | | | - Deepak Kanojia
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | | | - Yu Han
- Northwestern University, Chicago, USA
| | - Irina Balyasnikova
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Roger Stupp
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Catalina Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
10
|
Dapash M, Hou D, Castro B, Rashidi A, Zhang P, Stupp R, Miska J, Lesniak M, Chang C. EXTH-29. DUAL TGFB AND PD1 BLOCKADE PROMOTES GERMINAL-CENTER B-CELL IMMUNE RESPONSES AGAINST GLIOBLASTOMA. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
In contrast to other malignancies such as melanoma and sarcoma, Glioblastoma (GBM) remains difficult to treat with immunotherapies. Recent studies have shown that positive immunotherapeutic responses are mediated by the accumulation of germinal-center-like B cells which are predictive of survival in patients treated with neoadjuvant PD1 blockade. In contrast, GBM-associated B-cells are scarce and the establishment of germinal-center like cells have not been observed. This study seeks to identify how B-cells are driven towards their immunosuppressive phenotypes in GBM and how this prevents immunotherapeutic efficacy. Utilizing single-cell RNA sequencing (scRNA-seq) in a CT2A murine glioma model, TGFb receptors 1 and 3 were identified as the most highly expressed inhibitory receptors on GBM-associated B cells. Furthermore, using scRNA-seq, TGFb1 was identified as the most highly expressed immunosuppressive cytokine in the TME, which was produced principally by tumor-associated myeloid cells (TAMCs). Inhibiting the myeloid compartment using intracranial anti-Gr1 antibody in combination with PD1 blockade resulted in B-cells exhibiting greater proliferation and differentiation into memory B-cells in addition to germinal-center-like B-cells. Further demonstrating B-cell functional reprogramming, autologous T cells isolated from spleens exhibited greater proliferation and robust anti-tumor cytotoxicity when cocultured with tumor-associated B-cells from the dual treatment group. Finally, inhibiting a5b8 integrin, a key complex in releasing active TGFb, increased tumor-infiltrating proliferating B-cells and conferred a long-term survival benefit in the CT2A murine model. Our results demonstrate that the immunosuppressive TME of GBM is influenced by the vital interplay between B-cells and the TME through TGFb signaling. This study highlights the potential therapeutic benefits of targeting the TGFb signaling pathway in conjunction with the current standard of care for GBM.
Collapse
Affiliation(s)
| | - David Hou
- Northwestern University, Chicago, USA
| | - Brandyn Castro
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | | | - Roger Stupp
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Catalina Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
11
|
Lukas R, Sachdev S, Kumthekar P, Dixit K, Grimm S, Gondi V, Sharp L, Lezon R, James D, Lesniak M, Stupp R, Wainwright D. CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
IDHwt glioblastoma with unmethylated MGMT gene promoter carries a poor prognosis. Preclinical studies have shown that combination of radiotherapy and dual immunotherapy with nivolumab and IDO inhibition significantly prolongs survival of mice with an orthotopic glioblastoma [Ladomersky, et al. CCR 2018;24(11):2559-2573]. In a clinical trial in patients with newly diagnosed glioblastoma with unmethylated MGMT we substituted temozolomide for dual immunotherapy combination.
METHODS
Phase 1 trial [NCT04047706] using a 3 + 3 dose-escalation design. All received standard radiotherapy (30 x 2 Gy) with addition of once daily oral BMS-986205 and intravenous nivolumab (240mg every 2 weeks) begining on day 1 of radiotherapy and continuing until disease progression or intolerance. BMS-986205 dosing was increased from 50 mg to 100 mg. DLT period encompasses 6 weeks of radiotherapy and the 4 subsequent weeks. Immunocorrelatives being conducted before and after treatment include mass spectrometry for tryptophan and kynurenine levels, immunohistochemistry of resected tumor, and RNA-sequencing and flow cytometric analysis of PBMCs.
RESULTS
Twelve patients were treated on 2 dose levels of BMS-986205 (50, 100 mg). Treatment-emergent toxicity was as expected for this population. Three (25%) treatment-related SAEs were reported. Dose limiting toxicity of grade 3 transaminase elevation was observed in 2 patients at the 100 mg dose level, while at lower doses of BMS-986205 no substantial alterations of liver enzymes was observed. No other relevant treatment related toxicity occured. Ongoing immunocorrelative profiling and preliminary outcome data (all patients minimal follow-up >12 months) will be available at the time of the meeting.
CONCLUSIONS
Dose limiting toxicity of BMS-986205 in combination with nivolumab and radiotherapy is hepatic (reversible) transaminitis. The recommended dose for further investigation is 50 mg. Accrual is ongoing for the MGMT promoter methylated cohort using the same regimen without withholding temozolomide. A randomized phase 2/3 trial is approved within the NRG network.
Collapse
Affiliation(s)
- Rimas Lukas
- Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Chicago, IL, USA
| | | | - Priya Kumthekar
- Northwestern Medicine; Feinberg School of Medicine, Chicago, IL, USA
| | - Karan Dixit
- Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Chicago, IL, USA
| | - Sean Grimm
- Northwestern University, Chicago, IL, USA
| | - Vinai Gondi
- Northwestern University, Warrenville, IL, USA
| | | | - Ray Lezon
- Northwestern University, Chicago, IL, USA
| | | | | | - Roger Stupp
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | |
Collapse
|
12
|
Rashidi A, Cordero A, Castro B, Hou D, Dapash M, Zhang P, Han Y, Lopez-Rosas A, Chandel N, Lesniak M, Chang C, Miska J. TAMI-25. UPREGULATION OF CREATINE METABOLISM BY MYELOID CELLS RESULTS IN GLIOBLASTOMA PROGRESSION. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Malignant brain tumors are uniquely immunosuppressive, with a predominant infiltration of immunosuppressive tumor-associated myeloid cells (TAMCs) and a deficit in T-cells unrivaled to any other tumor. This unique tumor microenvironment (TME) promotes resistance to both conventional and immune therapies for this disease. The underlying mechanisms by which TAMCs promote glioblastoma (GBM) progression are not fully understood. We found that TAMCs specifically upregulate de-novo creatine metabolism within GBM using unbiased genetic and metabolic screening. This metabolic phenotype was confirmed in human GBM patients by comparing peripheral versus tumor-infiltrating myeloid cells. Examination of de-novo creatine generation using Carbon13 arginine flux revealed that TAMCs, but not tumor-infiltrating CD8+ T-cells, can produce creatine. Furthermore, we demonstrate that TAMCs actively secrete de-novo generated creatine into cell cultures. Examination of the single-cell microenvironment of GBM revealed that malignant cells preferentially express the creatine transporter, indicating that TAMC-derived creatine is taken up by GBM. Notably, SLC6A8 is directly upregulated in the context of hypoxia and suggests that creatine uptake is a mechanism to promote survival under hypoxic stress. Indeed, exogenous creatine supplementation promoted both the migration and survival of multiple glioblastoma cell lines in-vitro. Utilizing an established inhibitor of creatine metabolism, β-Guanidinopropionic acid (β -GPA), we found that β -GPA blocks both the migration and survival of glioma cells under hypoxic stress. Lastly, β -GPA also inhibited creatine secretion by TAMCs, showing that creatine blockade can also influence TAMC metabolic phenotype. In the future, we will examine the importance of creatine metabolism on both immune suppression and tumor progression in-vivo. This work provides novel insights into the role of creatine metabolism in GBM and identifies a unique therapeutic avenue for this devastating disease.
Collapse
Affiliation(s)
| | - Alex Cordero
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Brandyn Castro
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - David Hou
- Northwestern University, Chicago, IL, USA
| | | | - Peng Zhang
- Northwestern University, Chicago, IL, USA
| | - Yu Han
- Northwestern University, Chicago, IL, USA
| | | | | | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Catalina Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | |
Collapse
|
13
|
Dmello C, Sonabend A, Arrieta V, Zhang D, Kanojia D, Chen L, Gould A, Kane JR, Zhang J, Kang S, Winter J, Horbinski C, Győrffy B, Cordero A, Chang C, Castro B, Hsu P, Ahmed A, Lesniak M, Stupp R, Sonabend AM. BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Paclitaxel (PTX) is one the most potent and commonly used chemotherapies for breast and pancreatic cancer. Given the potency of this drug for glioblastomas (GBM) several ongoing clinical trials are investigating means of enhancing delivery of PTX across the blood-brain barrier for this disease. In spite of the efficacy of PTX, individual tumors exhibit variable susceptibility to this drug, with response rate in the range of 30%-60%. To identify predictive biomarkers for response to PTX, we performed a genome-wide CRISPR knock-out screen using human glioma cells. The most enriched genes in the CRISPR screen underwent further selection based on their correlation with survival in the breast cancer patient cohorts treated with PTX and not in patients treated with other chemotherapies, a finding that was validated on a second independent patient cohort. This led to the discovery of endoplasmic reticulum (ER) protein SSR3 as a putative predictive biomarker for PTX. SSR3 protein levels showed positive correlation with response to PTX in breast cancer cells, glioma cells, in multiple intracranial glioma xenografts and in GBM patient derived explant cultures. Knockout of SSR3 turned the cells resistant to PTX while its overexpression sensitized the cells to PTX. In gliomas, SSR3-mediated susceptibility to PTX relates to modulation of phosphorylation of ER stress sensor IRE1α. Thus, by using genome-wide screen combined with patient response data, we discovered a biomarker that demonstrates causal and correlative relationship with response to PTX in breast cancer and GBM. Prospective validation of this biomarker is warranted for its broad implementation for precision oncology.
Collapse
Affiliation(s)
| | - Aarón Sonabend
- Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Víctor Arrieta
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Daniel Zhang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Deepak Kanojia
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Li Chen
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | - J Robert Kane
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Jiangshan Zhang
- Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Seong Kang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Jan Winter
- Functional Genomics and Signaling, German Center for Cancer Research, Heidelberg, Germany
| | - Craig Horbinski
- Department of Pathology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
| | - Balázs Győrffy
- Semmelweis University Dept. of Bioinformatics, Budapest, Hungary and TTK Momentum Cancer Biomarker Research Group, Budapest, Hungary
| | - Alex Cordero
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Catalina Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Brandyn Castro
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Patrick Hsu
- Genomics Institute, University of California, Berkeley, CA, USA
| | - Atique Ahmed
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Roger Stupp
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Adam M Sonabend
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
14
|
Hou D, Castro B, Dapash M, Rashidi A, Zhang P, Han Y, Lopez-Rosas A, Lesniak M, Miska J, Chang C. IMMU-36. B CELL-VACCINE ELICITS LONG TERM IMMUNITY AGAINST GLIOBLASTOMA VIA ACTIVATION AND DIFFERENTIATION OF TUMOR-SPECIFIC CD8+ MEMORY T CELLS. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
While immunotherapy is used clinically to treat many cancers, its translation into brain tumors remains elusive. The importance of B cells in cancer immunity has become increasingly clear, and we previously developed a B cell-based cellular vaccine (BVax) against glioblastoma (GBM) by further activating 4-1BBL+ B cells with CD40 agonism and IFNγ. BVax were characterized as professional antigen-presenting cells (APCs) that promote CD8+ T cell migration and persistence in murine tumor-bearing brains. This study seeks to understand the mechanisms underlying BVax-induced CD8+ T cell fitness in the tumor microenvironment. Initial transcriptomic analysis highlighted that Bvax express high levels of IL15Rα, indicating their potential ability to trans-present IL15. Considering IL15 trans-presentation is fundamental in T-cell memory differentiation, we used BVax to induce T cell activation in the presence of exogenous IL15. BVax were better capable of activating antigen-specific CD8+ T cells and promoting a memory phenotype when compared to other professional APCs such as dendritic cells (DCs). T cell receptor (TCR) CDR3β sequencing showed that BVax expanded a number of TCR clones in-vitro that were found in brains of CT2A tumor-bearing mice in-vivo. These BVax-activated CD8+ T cells displayed a stronger antigen recall response and unique metabolic profile compared to DC-activated CD8+ T cells as shown by metabolomic analysis of tumor-infiltrating CD8+ T cells. When comparing the anti-tumor effects of CD8+ T cells activated by various APCs, BVax with exogenous IL15 promoted CD8+ T cells that displayed the most potent cytotoxicity against GBM cells in-vitro. Collectively, this study suggests that the IL15/IL15Rα axis and interactions with CD8+ T cell are key factors of BVax therapy in promoting a robust survival benefit and long-term immunologic memory against GBM in preclinical models. Additionally, the development of T cell therapies based on B cell licensing can be a promising future approach for glioblastoma therapy.
Collapse
Affiliation(s)
- David Hou
- Northwestern University, Chicago, IL, USA
| | - Brandyn Castro
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | | | - Peng Zhang
- Northwestern University, Chicago, IL, USA
| | - Yu Han
- Northwestern University, Chicago, IL, USA
| | | | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | - Catalina Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
15
|
Lee Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga R, Torres IJ, Xiao T, Arrieta V, Zhang D, Lopez-Rosas A, Han Y, Sonabend A, Horbinski C, Stupp R, Balyasnikova I, Lesniak M. EXTH-43. GENERATION OF A B-CELL-BASED VACCINE FOR THE TREATMENT OF GLIOBLASTOMA. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Immunotherapy has revolutionized the treatment of many tumors. However, most glioblastoma (GBM) patients have not, so far, benefited from such successes. With the goal of exploring ways to boost anti-GBM immunity, we developed a B-cell-based vaccine (BVax) that consists of 4-1BBL+ B cells activated with CD40 agonism and IFNg stimulation. BVaxmigrate to key secondary lymphoid organs and are proficient at antigen cross-presentation, which promotes both the survival and functionality of CD8+ T cells. A combination of radiation, BVax, and PD-L1 blockade conferred tumor eradication in 80% of treated tumor-bearing animals. This treatment elicited immunologic memory that prevented the growth of new tumors upon subsequent re-injection in cured mice. GBM patient-derived BVax were successful in activating autologous CD8+ T cells; these T cells showed a strong ability to kill autologous glioma cells. In addition to the role in activating CD8+ T cells, BVax produce tumor-specific antibodies able to control tumor growth via antibody-mediated cell cytotoxicity. In conclusion, BVax tackles GBM immunosurveillance escape by using both cellular (CD8+ T-cell activation) and humoral (anti-tumor antibody production) immunity. Our study provides an efficient alternative to current immunotherapeutic approaches that can be readily translated to the clinic.
Collapse
Affiliation(s)
| | | | - David Hou
- Northwestern University, Chicago, IL, USA
| | | | - Peng Zhang
- Northwestern University, Chicago, IL, USA
| | | | | | - Ting Xiao
- Northwestern University, Chicago, IL, USA
| | | | | | | | - Yu Han
- Northwestern University, Chicago, IL, USA
| | - Adam Sonabend
- Lurie Cancer Center, Malnati Brain Tumor Institute, Department of Neurosurgery, Northwestern University, Chicago, IL, USA
| | | | | | | | | |
Collapse
|
16
|
Lesniak M, Mach G, Starzyk B, Baranowska A, Bik M, Kochanowicz M, Zmojda J, Miluski P, Sitarz M, Dorosz D. Investigation of the structure in oxyfluoride TeO2–P2O5 based glasses with the various BaF2 content. J Mol Struct 2020. [DOI: 10.1016/j.molstruc.2020.128452] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Rashidi A, Miska J, Lee-Chang C, Kanojia D, Panek W, Lopez-Rosas A, Han Y, Kim J, Pituch K, Lesniak M. IMMU-06. ABSENCE OF THE AMINO ACID STRESS-SENSOR GCN2 REDUCES SUPPRESSIVE EFFECTS OF MDSCs IN GLIOMA. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Jason Miska
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | | | | | - Aurora Lopez-Rosas
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Yu Han
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Julius Kim
- Northwestern University, Chicago, IL, USA
| | | | | |
Collapse
|
18
|
Kloeppinger L, Amidei C, Lesniak M, Stupp R, Chandler J, Tate M, Sonabend A, Bloch O, Lukas R, Sachdev S, Kumthekar P, Dixit K. QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.897] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | | | - Roger Stupp
- Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
| | | | | | | | - Orin Bloch
- Northwestern University, Chicago, IL, USA
| | | | | | | | | |
Collapse
|
19
|
Chang CL, Miska J, Rashidi A, Zhang P, Appin C, Xiao T, Lopez-Rosas A, Han Y, Lesniak M. IMMU-11. IDENTIFICATION OF GLIOMA-ASSOCIATED REGULATORY B CELLS AND EFFECTS OF RITUXIMAB IMMUNOTHERAPY. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Catalina Lee Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Jason Miska
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Aida Rashidi
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Peng Zhang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Christina Appin
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Ting Xiao
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Aurora Lopez-Rosas
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Yu Han
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | |
Collapse
|
20
|
Pituch K, Zannikou M, Ilut L, Chen C, Lesniak M, Gottschalk S, Krenciute G, Balyasnikova I. EXTH-32. TRANSGENIC EXPRESSION OF IL15 IMPROVES THE EFFICACY OF CAR T CELLS IN AN IMMUNE COMPETENT GLIOBLASTOMA MODEL. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | - Irina Balyasnikova
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
21
|
Jadach R, Zmojda J, Kochanowicz M, Miluski P, Pisarska J, Pisarski WA, Sołtys M, Lesniak M, Sitarz M, Dorosz D. Investigation of the aluminum oxide content on structural and optical properties of germanium glasses doped with RE ions. Spectrochim Acta A Mol Biomol Spectrosc 2018; 201:143-152. [PMID: 29747084 DOI: 10.1016/j.saa.2018.04.043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 04/13/2018] [Accepted: 04/22/2018] [Indexed: 06/08/2023]
Abstract
In this paper structural and optical properties of Rare Earth doped (RE) gallo-germanate glasses modified with various amount of Al2O3 have been investigated. Glasses doped with Yb3+, Tm3+, and Ho3+ ions were synthesized to study Al2O3 additive influence on their structural and emission properties in the visible spectral region. MIR spectra indicated that the structure of prepared glasses tends to order and its polymerization along with the aluminum content increase. Glass samples consisting of the low molar content of Al2O3 are characterized by a significant contribution of Tm3+ ions in light emission while Ho3+ ions luminescence dominates in samples consisting of the higher molar content of Al2O3. Additionally, investigation of light emission in visible range showed that samples consisting of the low molar content of Al2O3 are characterized by greenish blue light emission whereas light emitted by samples consisting of 15-20 mol% is much closer to the white colour.
Collapse
Affiliation(s)
- R Jadach
- AGH University of Science and Technology, Faculty of Materials Science and Ceramics, A. Mickiewicza Street, 30-059 Krakow, Poland
| | - J Zmojda
- Bialystok University of Technology, Faculty of Electrical Engineering, Wiejska Street 45D, 15-351 Bialystok, Poland
| | - M Kochanowicz
- Bialystok University of Technology, Faculty of Electrical Engineering, Wiejska Street 45D, 15-351 Bialystok, Poland
| | - P Miluski
- Bialystok University of Technology, Faculty of Electrical Engineering, Wiejska Street 45D, 15-351 Bialystok, Poland
| | - J Pisarska
- University of Silesia, Institute of Chemistry, Szkolna 9, 40-007 Katowice, Poland
| | - W A Pisarski
- University of Silesia, Institute of Chemistry, Szkolna 9, 40-007 Katowice, Poland
| | - M Sołtys
- University of Silesia, Institute of Chemistry, Szkolna 9, 40-007 Katowice, Poland
| | - M Lesniak
- AGH University of Science and Technology, Faculty of Materials Science and Ceramics, A. Mickiewicza Street, 30-059 Krakow, Poland
| | - M Sitarz
- AGH University of Science and Technology, Faculty of Materials Science and Ceramics, A. Mickiewicza Street, 30-059 Krakow, Poland
| | - D Dorosz
- AGH University of Science and Technology, Faculty of Materials Science and Ceramics, A. Mickiewicza Street, 30-059 Krakow, Poland.
| |
Collapse
|
22
|
Frelek-Kozak M, Kurpaska L, Lesniak M, Jozwik I, Jagielski J. Mechanical and structural properties of ODS RAF steels submitted to low-energy ions irradiation. Fusion Engineering and Design 2018. [DOI: 10.1016/j.fusengdes.2017.12.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
23
|
Platonov ME, Borovjagin AV, Kaverina N, Xiao T, Kadagidze Z, Lesniak M, Baryshnikova M, Ulasov IV. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Lett 2017; 417:75-88. [PMID: 29269086 DOI: 10.1016/j.canlet.2017.12.024] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 12/13/2017] [Accepted: 12/14/2017] [Indexed: 12/12/2022]
Abstract
KISS1 tumor suppressor protein regulates cancer cell invasion via MMP9 metalloproteinase. Downregulation of KISS1 gene expression promotes progression of breast cancer and melanoma, resulting in the development of distant metastases. In the current study, we investigated whether restoration of KISS1 expression in KISS1-deficient human metastatic breast cancer cells holds potential as an advanced anticancer strategy. To this end we engineered an infectivity-enhanced conditionally-replicative human adenovirus type 5 encoding KISS1 as an "arming" transgene in the Ad5 E3 region for an ectopic KISS1 expression in transduced cancer cells. The oncolytic potential of the vector was examined using brain-invading metastatic clones of CN34 and MDA-MB-231 breast cancer cells, which supported high levels of AdKISS1 replication, correlating with a robust CRAd-mediated cytotoxicity. Secretion of cellular factors responsible for tumor angiogenesis, cell-to-cell communication and anti-tumoral immune responses upon KISS1 expression in breast cancer cells was analyzed by a RayBiotech Kiloplex Quantibody array. Overall, our results indicate that KISS1 transgene expression provides an important benefit for CRAd-mediated cytotoxicity in breast cancer cells and holds potential as an anticancer treatment in conjunction with oncolytic virotherapy of breast and other metastatic cancers.
Collapse
Affiliation(s)
- Mikhail E Platonov
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, 119991, Russia
| | - Anton V Borovjagin
- Institute of Oral Health Research, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Natalya Kaverina
- N.N. Blokhin Cancer Research Center, RAMN, Kashirskoe Shosse 23, Moscow, 115478, Russia
| | - Ting Xiao
- Department of Neurological Surgery, Northwestern University, Chicago, 60611, USA
| | - Zaira Kadagidze
- N.N. Blokhin Cancer Research Center, RAMN, Kashirskoe Shosse 23, Moscow, 115478, Russia
| | - Maciej Lesniak
- Department of Neurological Surgery, Northwestern University, Chicago, 60611, USA
| | - Marya Baryshnikova
- N.N. Blokhin Cancer Research Center, RAMN, Kashirskoe Shosse 23, Moscow, 115478, Russia
| | - Ilya V Ulasov
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, 119991, Russia.
| |
Collapse
|
24
|
Wu M, Miska J, Zhang P, Kane JR, Xiao T, Balyasnikova I, Chandler J, Horbinski C, Lesniak M. PATH-44. RACE INFLUENCES PATIENT SURVIVAL IN GLIOMA AND ASSOCIATES WITH GENETIC MARKERS OF RETINOIC ACID METABOLISM. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.734] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
25
|
Chastkofsky M, Procissi D, Yang C, Goldman S, Lesniak M, Hashizume R, Balyasnikova I. DIPG-19. MESENCHYMAL STEM CELLS TARGET DIFFUSE INTRINSIC PONTINE GLIOMA IN MICE AFTER INTRANASAL DELIVERY. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Jasinski J, Kurpaska L, Lubas M, Lesniak M, Jasinski J, Sitarz M. Effect of hybrid oxidation on the titanium oxide layer's properties investigated by spectroscopic methods. J Mol Struct 2016. [DOI: 10.1016/j.molstruc.2016.02.080] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
27
|
Kurpaska L, Gapinska M, Jasinski J, Lesniak M, Sitarz M, Nowakowska-Langier K, Jagielski J, Wozniak K. Influence of Ar-irradiation on structural and nanomechanical properties of pure zirconium measured by means of GIXRD and nanoindentation techniques. J Mol Struct 2016. [DOI: 10.1016/j.molstruc.2016.03.053] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Kim JW, Kane J, Young J, Yu D, Miska J, Chang A, Rashidi A, Ahmed A, Balyasnikova I, Lesniak M. IMST-46. DENDRITIC CELL-BASED IMMUNOTHERAPY FOR MALIGNANT GLIOMA BY WAY OF A NOVEL DENDRITIC CELL-TARGETED (scFvDEC205) ADENOVIRAL VECTOR. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Atashi F, Hasan T, Lee G, Guo D, Park C, Lesniak M, James CD, Ahmed A. STMC-16. EZH2-MEDIATED ARL13B REGULATE CILIOGENESIS IN GBM. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Hasan T, Atashi F, Kim J, Guo D, Park C, Wu M, Dey M, Lesniak M, Horbinski C, Ahmed A. STMC-34. ROLE OF INTERLEUKIN-8/CXCR2 REGULATED EPIGENETIC PLASTICITY IN GBM RECURRENCE. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
James CD, Ahmed A, Raizer J, Lesniak M, Horbinski C, Kumthekar P. TMOD-08. PDX MODELING OF RECURRENT GLIOBLASTOMA FOR TESTING SALVAGE THERAPIES. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Auffinger B, Hasan T, Lee G, Tobias A, Deheeger M, Han Y, Guo D, Lesniak M, James CD, Ahmed A. TMIC-24. THE CONTRIBUTION OF VASCULAR CO-OPTION AND TUMOR-DERIVED ENDOTHELIAL CELLS TO GBM RECURRENCE. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Kumthekar P, Ahmed A, Lesniak M, James CD, Horbinski C. TMOD-26. DEVELOPING PATIENT-DERIVED XENOGRAFT MODELS OF METASTATIC CANCER TO THE BRAIN. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Zhang P, Yu D, Han Y, Wu M, Lesniak M. EXTH-53. STEALTH LIPID NANO-ENCAPSULATION ENABLES EFFICACIOUS THERAPEUTIC RNA INTERFERENCE IN MALIGNANT GLIOMA. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
|
36
|
Krishnan V, Mitchell K, Miska J, George S, Shaw P, Seewaldt V, Lesniak M, Chekmareva M, Becker L, Parkash V, Miranti C, Rinker-Schaeffer C. Abstract A82: Ovarian cancer cells hijack immune functions of omental milky spots for metastatic colonization. Clin Cancer Res 2016. [DOI: 10.1158/1557-3265.ovca15-a82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The omentum is the primary site of metastasis in both ovarian cancer models and clinical disease. It is composed predominantly of adipose studded with lymphoreticular organs (milky spots), distinguishing it from other peritoneal adipose. Milky spots are specialized for immune cell trafficking and peritoneal surveillance. We and others have shown that ovarian cancer cells exploit the physiologic function(s) of these structures for omental metastatic colonization. The purpose of this study was to identify cellular and molecular mechanisms responsible for ovarian cancer homing to and growth within milky spot structures.
Experimental Procedures: Quantitative in vivo and ex vivo assays were used to evaluate human (SKOV3ip.1, HEYA8, and CaOV3) and murine (ID8) ovarian cancer cell localization to milky spots on the murine omental fat band. Assays were conducted using C57/Bl6 mice or those lacking B cells (Igh6-/-); T cells (Nude); B and T cells (Rag1-/-); or B, T, and NK cells (BN XID). In vitro assays were used to assess the migration-promoting activity of omentum- and macrophage-conditioned media. Standard approaches were used to assess protein expression, cell growth and viability, etc.
Rationale: Milky spots provide resident tissue macrophages and lymphocytes needed for peritoneal homeostasis. Macrophages and stromal cells secrete chemokines promoting peritoneal lymphocyte homing to the omentum. In response to peritoneal irritants, activated CD11b+ milky spot macrophages organize coordinated expansion of vascular and stromal compartments. The increase in both the number and size of milky spots is needed to process particulates, resolve infections, and encapsulate foreign bodies.
Hypothesis: CD11b+ cells secrete homeostatic chemokines promoting G-protein-dependent migration of ovarian cancer cells to milky spots. Ovarian cancer cell binding to adhesion molecules on the milky spot surface activates CD11b+ cell-dependent tissue remodeling, creating a microenvironment promoting ovarian cancer growth.
New Findings: Consistent with our hypothesis, in vivo assays showed that macrophage depletion prior to injection of ID8 and SKOV3ip.1 cells prevented microscopic metastasis formation. In vitro assays found that macrophages are required for ovarian cancer cell localization to milky spots. These data prompt the hypothesis that CD11b+ cells produce a factor(s) responsible for the migration-promoting ability of omentum-conditioned media.
To test this, media was conditioned by omental adipose isolated from mice after macrophage depletion. In support of our hypothesis, the migration-promoting activity of macrophage-depleted omentum-conditioned media was on a par with that of media conditioned by milky spot-deficient adipose. Further, media conditioned by CD11b+ cells recapitulates the migration-promoting activity exhibited by omentum-conditioned media.
In vitro and ex vivo assays were used to test whether ovarian cancer cells utilize mechanisms analogous to lymphocyte trafficking for milky spot homing. Specifically, cells were pretreated with pertussis toxin or vehicle alone, and then evaluated for migration in response to omentum-conditioned media and milky spot localization ex vivo. Consistent with data reported for lymphocyte homing, pertussis toxin pre-treatment caused a 40% to 50% reduction in ovarian cancer cell homing.
Conclusions and Current Efforts: Our data support a model in which CD11b+ macrophages secrete one or more chemokines promoting G-protein receptor-dependent ovarian cancer cell migration, and potentially integrin activation, which mediate milky spot homing. Current experiments focus on identification of integrin-ligand interactions, CD11b+ cell activation, and defining the link between ovarian cancer cell growth and increase in milky spot size and number.
Citation Format: Venkatesh Krishnan, Kelly Mitchell, Jason Miska, Sophia George, Patricia Shaw, Victoria Seewaldt, Maciej Lesniak, Marina Chekmareva, Lev Becker, Vinita Parkash, Cindy Miranti, Carrie Rinker-Schaeffer. Ovarian cancer cells hijack immune functions of omental milky spots for metastatic colonization. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A82.
Collapse
Affiliation(s)
| | | | - Jason Miska
- 2University of Chicago School of Medicine, Chicago, IL,
| | | | | | | | | | | | - Lev Becker
- 2University of Chicago School of Medicine, Chicago, IL,
| | | | | | | |
Collapse
|
37
|
Gutova M, Shahmanyan D, Oganesyan D, Abramyants Y, Danielyan L, Frey W, Khankaldyyan V, Najbauer J, Balyasnikova I, Moats R, Lesniak M, Barish M, Aboody K. ATPS-29INTRANASAL DELIVERY OF THERAPEUTIC NEURAL STEM CELLS TO TARGET INTRACEREBRAL GLIOMA. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov204.29] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Yu D, Cheng SH, Tsai HM, Kanojia D, Leoni L, Aboody K, Chen CT, Lesniak M, Balyasnikova I. BMET-40NANO PLATFORM FOR DYNAMIC IN VIVO TRACKING OF NEURAL STEM CELLS TO BRAIN METASTASES OF BREAST CANCER. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov208.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Krenciute G, Krebs S, Torres D, Lesniak M, Balyasnikova I, Gottschalk S. IM-02 * A scFv-BASED CAR TO REDIRECT T CELLS TO IL13R 2-POSITIVE PEDIATRIC GLIOMA. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov061.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Krenciute G, Krebs S, Torres D, Lesniak M, Balyasnikova I, Gottschalk S. 282. A scFv-Based CAR To Redirect T Cells To IL13Ra2-Positive Glioma. Mol Ther 2015. [DOI: 10.1016/s1525-0016(16)33891-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
41
|
Dey M, Chang A, Wainwright D, Ahmed A, Han Y, Lesniak M. IT-07 * COMPARATIVE EVALUATION OF pDCs AND mDCs FOR DENDRITIC CELL BASED VACCINE STRATEGY FOR MALIGNANT GLIOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou258.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Auffinger B, Tobias A, Han Y, Lee G, Guo D, Dey M, Lesniak M, Ahmed A. SC-02 * CONVERSION OF DIFFERENTIATED CANCER CELLS INTO CANCER STEM-LIKE CELLS IN A GLIOBLASTOMA MODEL AFTER PRIMARY CHEMOTHERAPY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou275.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
43
|
Qiao J, Dey M, Chang A, Woongki K, Han Y, Zhang L, Lesniak M. IT-27 * ONCOLYTIC ADENOVIRUSES-MEDIATED IMMUNE RESPONSES IN SYNGENEIC MURINE GLIOMA MODEL. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou258.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Balyasnikova I, Dey M, Tobias A, Kanojia D, Lee G, Han Y, Zhang L, Ahmed A, Aboody K, Lesniak M. ET-05 * INTRANASAL DELIVERY OF NEURAL STEM CELLS LOADED WITH ONCOLYTIC ADENOVIRUS EXTENDS SURVIVAL OF MICE WITH INTRACRANIAL GLIOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou255.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Barish M, Weng L, D'Apuzzo M, Forman S, Brown C, Ben Horin I, Volovitz I, Ram Z, Chang A, Wainwright D, Dey M, Han Y, Lesniak M, Chow K, Yi J, Shaffer D, Gottschalk S, Clark A, Safaee M, Oh T, Ivan M, Kaur R, Sun M, Lu YJ, Ozawa T, James CD, Bloch O, Parsa A, Debinski W, Choi YA, Gibo DM, Dey M, Wainwright D, Chang A, Han Y, Lesniak M, Herold-Mende C, Mossemann J, Jungk C, Ahmadi R, Capper D, von Deimling A, Unterberg A, Beckhove P, Jiang H, Klein SR, Piya S, Vence L, Yung WKA, Sawaya R, Heimberger A, Conrad C, Lang F, Gomez-Manzano C, Fueyo J, Jung TY, Choi YD, Kim YH, Lee JJ, Kim HS, Kim JS, Kim SK, Jung S, Cho D, Kosaka A, Ohkuri T, Okada H, Erickson K, Malone C, Ha E, Soto H, Hickey M, Owens G, Liau L, Prins R, Minev B, Kruse C, Lee J, Dang X, Borboa A, Coimbra R, Baird A, Eliceiri B, Mathios D, Lim M, Ruzevick J, Nicholas S, Polanczyk M, Jackson C, Taube J, Burger P, Martin A, Xu H, Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M, Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, Watkins S, Sarkar S, Okada H, Pellegatta S, Pessina S, Cantini G, Kapetis D, Finocchiaro G, Avril T, Vauleon E, Hamlat A, Mosser J, Quillien V, Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hamburdzumyan D, Finke J, Vogelbaum M, Renner D, Litterman A, Balgeman A, Jin F, Hanson L, Gamez J, Carlson B, Sarkaria J, Parney I, Ohlfest J, Pirko I, Pavelko K, Johnson A, Sims J, Grinshpun B, Feng Y, Amendolara B, Shen Y, Canoll P, Sims P, Bruce J, Lee SX, Wong E, Swanson K, Wainwright D, Chang A, Dey M, Balyasnikova I, Cheng Y, Han Y, Lesniak M, Wang F, Wei J, Xu S, Ling X, Yaghi N, Kong LY, Doucette T, Weinberg J, DeMonte F, Lang F, Prabhu S, Heimberger A, Wiencke J, Accomando W, Houseman EA, Nelson H, Wrensch M, Wiemels J, Zheng S, Hsuang G, Bracci P, Kelsey K. IMMUNOLOGY RESEARCH. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, Hampton C, Decker W, Chiba Y, Hashimoto N, Kagawa N, Hirayama R, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Yoshimine T, Choi B, Gedeon P, Herndon J, Sanchez-Perez L, Mitchell D, Bigner D, Sampson J, Choi YA, Pandya H, Gibo DM, Debinski W, Cloughesy TF, Liau LM, Chiocca EA, Jolly DJ, Robbins JM, Ostertag D, Ibanez CE, Gruber HE, Kasahara N, Vogelbaum MA, Kesari S, Mikkelsen T, Kalkanis S, Landolfi J, Bloomfield S, Foltz G, Pertschuk D, Everson R, Jin R, Safaee M, Lisiero D, Odesa S, Liau L, Prins R, Gholamin S, Mitra SS, Richard CE, Achrol A, Kahn SA, Volkmer AK, Volkmer JP, Willingham S, Kong D, Shin JJ, Monje-Deisseroth M, Cho YJ, Weissman I, Cheshier SH, Kanemura Y, Sumida M, Yoshioka E, Yamamoto A, Kanematsu D, Takada A, Nonaka M, Nakajima S, Goto S, Kamigaki T, Takahara M, Maekawa R, Shofuda T, Moriuchi S, Yamasaki M, Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E, Lin Y, Wang Y, Qiu X, Jiang T, Lin Y, Wang Y, Jiang T, Zhang G, Wang J, Okada H, Butterfield L, Hamilton R, Drappatz J, Engh J, Amankulor N, Lively M, Chan M, Salazar A, Potter D, Shaw E, Lieberman F, Pandya H, Choi Y, Park J, Phuphanich S, Wheeler C, Rudnick J, Hu J, Mazer M, Wang H, Nuno M, Guevarra A, Sanchez C, Fan X, Ji J, Chu R, Bender J, Hawkins E, Black K, Yu J, Reap E, Archer G, Sanchez-Perez L, Norberg P, Schmittling R, Nair S, Cui X, Snyder D, Chandramohan V, Choi B, Kuan CT, Mitchell D, Bigner D, Yan H, Sampson J, Reardon D, Li G, Recht L, Fink K, Nabors L, Tran D, Desjardins A, Chandramouli N, Duic JP, Groves M, Clarke A, Hawthorne T, Green J, Yellin M, Sampson J, Rigakos G, Spyri O, Nomikos P, Stavridi F, Grossi I, Theodorakopoulou I, Assi A, Kouvatseas G, Papadopoulou E, Nasioulas G, Labropoulos S, Razis E, Rudnick J, Ravi A, Sanchez C, Tang DN, Hu J, Yu J, Sharma P, Black K, Sengupta S, Sampath P, Soto H, Erickson K, Malone C, Hickey M, Ha E, Young E, Ellingson B, Prins R, Liau L, Kruse C, Sul J, Hilf N, Kutscher S, Schoor O, Lindner J, Reinhardt C, Kreisl T, Iwamoto F, Fine H, Singh-Jasuja H, Teijeira L, Gil-Arnaiz I, Hernandez-Marin B, Martinez-Aguillo M, Sanchez SDLC, Viudez A, Hernandez-Garcia I, Lecumberri MJ, Grandez R, de Lascoiti AF, Garcia RV, Thomas A, Fisher J, Baron U, Olek S, Rhodes H, Gui J, Hampton T, Tafe L, Tsongalis G, Lefferts J, Wishart H, Kleen J, Miller M, Ernstoff M, Fadul C, Vlahovic G, Desjardins A, Peters K, Ranjan T, Herndon J, Friedman A, Friedman H, Bigner D, Archer G, Lally-Goss D, Sampson J, Wainwright D, Dey M, Chang A, Cheng Y, Han Y, Lesniak M, Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Yu J, Rudnick J, Hu J, Phuphanich S, Mazer M, Wang H, Xu M, Nuno M, Patil C, Chu R, Black K, Wheeler C. IMMUNOTHERAPY/BIOLOGICAL THERAPIES. Neuro Oncol 2013; 15:iii68-iii74. [PMCID: PMC3823893 DOI: 10.1093/neuonc/not178] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2023] Open
|
47
|
Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, Silber J, Harinath G, Chan TA, Huse JT, Anai S, Hide T, Nakamura H, Makino K, Yano S, Kuratsu JI, Balyasnikova IV, Prasol MS, Kanoija DK, Aboody KS, Lesniak MS, Barone T, Burkhart C, Purmal A, Gudkov A, Gurova K, Plunkett R, Barton K, Misuraca K, Cordero F, Dobrikova E, Min H, Gromeier M, Kirsch D, Becher O, Pont LB, Kloezeman J, van den Bent M, Kanaar R, Kremer A, Swagemakers S, French P, Dirven C, Lamfers M, Leenstra S, Pont LB, Balvers R, Kloezeman J, Kleijn A, Lawler S, Leenstra S, Dirven C, Lamfers M, Gong X, Andres A, Hanson J, Delashaw J, Bota D, Chen CC, Yao NW, Chuang WJ, Chang C, Chen PY, Huang CY, Wei KC, Cheng Y, Dai Q, Morshed R, Han Y, Auffinger B, Wainwright D, Zhang L, Tobias A, Rincon E, Thaci B, Ahmed A, He C, Lesniak M, Choi YA, Pandya H, Gibo DM, Fokt I, Priebe W, Debinski W, Chornenkyy Y, Agnihotri S, Buczkowicz P, Rakopoulos P, Morrison A, Barszczyk M, Becher O, Hawkins C, Chung S, Decollogne S, Luk P, Shen H, Ha W, Day B, Stringer B, Hogg P, Dilda P, McDonald K, Moore S, Hayden-Gephart M, Bergen J, Su Y, Rayburn H, Edwards M, Scott M, Cochran J, Das A, Varma AK, Wallace GC, Dixon-Mah YN, Vandergrift WA, Giglio P, Ray SK, Patel SJ, Banik NL, Dasgupta T, Olow A, Yang X, Mueller S, Prados M, James CD, Haas-Kogan D, Dave ND, Desai PB, Gudelsky GA, Chow LML, LaSance K, Qi X, Driscoll J, Driscoll J, Ebsworth K, Walters MJ, Ertl LS, Wang Y, Berahovic RD, McMahon J, Powers JP, Jaen JC, Schall TJ, Eroglu Z, Portnow J, Sacramento A, Garcia E, Raubitschek A, Synold T, Esaki S, Rabkin S, Martuza R, Wakimoto H, Ferluga S, Tome CL, Debinski W, Forde HE, Netland IA, Sleire L, Skeie B, Enger PO, Goplen D, Giladi M, Tichon A, Schneiderman R, Porat Y, Munster M, Dishon M, Weinberg U, Kirson E, Wasserman Y, Palti Y, Giladi M, Porat Y, Schneiderman R, Munster M, Weinberg U, Kirson E, Palti Y, Gramatzki D, Staudinger M, Frei K, Peipp M, Weller M, Grasso C, Liu L, Becher O, Berlow N, Davis L, Fouladi M, Gajjar A, Hawkins C, Huang E, Hulleman E, Hutt M, Keller C, Li XN, Meltzer P, Quezado M, Quist M, Raabe E, Spellman P, Truffaux N, van Vurden D, Wang N, Warren K, Pal R, Grill J, Monje M, Green AL, Ramkissoon S, McCauley D, Jones K, Perry JA, Ramkissoon L, Maire C, Shacham S, Ligon KL, Kung AL, Zielinska-Chomej K, Grozman V, Tu J, Viktorsson K, Lewensohn R, Gupta S, Mladek A, Bakken K, Carlson B, Boakye-Agyeman F, Kizilbash S, Schroeder M, Reid J, Sarkaria J, Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS, Hashizume R, Tom M, Ihara Y, Ozawa T, Santos R, Torre JDL, Lepe E, Waldman T, Prados M, James D, Hashizume R, Ihara Y, Huang X, Yu-Jen L, Tom M, Mueller S, Gupta N, Solomon D, Waldman T, Zhang Z, James D, Hayashi T, Adachi K, Nagahisa S, Hasegawa M, Hirose Y, Gephart MH, Moore S, Bergen J, Su YS, Rayburn H, Scott M, Cochran J, Hingtgen S, Kasmieh R, Nesterenko I, Figueiredo JL, Dash R, Sarkar D, Fisher P, Shah K, Horne E, Diaz P, Stella N, Huang C, Yang H, Wei K, Huang T, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, Rodriguez-Aguirre M, Ibanez C, Kasahara N, Gunzburg W, Gruber H, Pertschuk D, Jolly D, Robbins J, Hurwitz B, Yoo JY, Bolyard C, Yu JG, Wojton J, Zhang J, Bailey Z, Eaves D, Cripe T, Old M, Kaur B, Serwer L, Yoshida Y, Le Moan N, Santos R, Ng S, Butowski N, Krtolica A, Ozawa T, Cary SPL, James CD, Johns T, Greenall S, Donoghue J, Adams T, Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Wirtz CR, Debatin KM, Halatsch ME, Karpel-Massler G, Kast RE, Westhoff MA, Merkur N, Dwucet A, Wirtz CR, Debatin KM, Halatsch ME, Kievit F, Stephen Z, Wang K, Kolstoe D, Silber J, Ellenbogen R, Zhang M, Kitange G, Schroeder M, Sarkaria J, Kleijn A, Haefner E, Leenstra S, Dirven C, Lamfers M, Knubel K, Pernu BM, Sufit A, Pierce AM, Nelson SK, Keating AK, Jensen SS, Kristensen BW, Lachowicz J, Demeule M, Regina A, Tripathy S, Curry JC, Nguyen T, Castaigne JP, Le Moan N, Serwer L, Yoshida Y, Ng S, Davis T, Santos R, Davis A, Tanaka K, Keating T, Getz J, Kapp GT, Romero JM, Ozawa T, James CD, Krtolica A, Cary SPL, Lee S, Ramisetti S, Slagle-Webb B, Sharma A, Connor J, Lee WS, Maire C, Kluk M, Aster JC, Ligon K, Sun S, Lee D, Ho ASW, Pu JKS, Zhang ZQ, Lee NP, Day PJR, Leung GKK, Liu Z, Liu X, Madhankumar AB, Miller P, Webb B, Connor JR, Yang QX, Lobo M, Green S, Schabel M, Gillespie Y, Woltjer R, Pike M, Lu YJ, Torre JDL, Waldman T, Prados M, Ozawa T, James D, Luchman HA, Stechishin O, Nguyen S, Cairncross JG, Weiss S, Lun X, Wells JC, Hao X, Zhang J, Grinshtein N, Kaplan D, Luchman A, Weiss S, Cairncross JG, Senger D, Robbins S, Madhankumar A, Slagle-Webb B, Rizk E, Payne R, Park A, Pang M, Harbaugh K, Connor J, Wilisch-Neumann A, Pachow D, Kirches E, Mawrin C, McDonell S, Liang J, Piao Y, Nguyen N, Yung A, Verhaak R, Sulman E, Stephan C, Lang F, de Groot J, Mizobuchi Y, Okazaki T, Kageji T, Kuwayama K, Kitazato KT, Mure H, Hara K, Morigaki R, Matsuzaki K, Nakajima K, Nagahiro S, Kumala S, Heravi M, Devic S, Muanza T, Nelson SK, Knubel KH, Pernu BM, Pierce AM, Keating AK, Neuwelt A, Nguyen T, Wu YJ, Donson A, Vibhakar R, Venkatamaran S, Amani V, Neuwelt E, Rapkin L, Foreman N, Ibrahim F, New P, Cui K, Zhao H, Chow D, Stephen W, Nozue-Okada K, Nagane M, McDonald KL, Ogawa D, Chiocca E, Godlewski J, Ozawa T, Yoshida Y, Santos R, James D, Pang M, Liu X, Madhankumar AB, Slagle-Webb B, Patel A, Miller P, Connor J, Pasupuleti N, Gorin F, Valenzuela A, Leon L, Carraway K, Ramachandran C, Nair S, Quirrin KW, Khatib Z, Escalon E, Melnick S, Phillips A, Boghaert E, Vaidya K, Ansell P, Shalinsky D, Zhang Y, Voorbach M, Mudd S, Holen K, Humerickhouse R, Reilly E, Huang T, Parab S, Diago O, Espinoza FL, Martin B, Ibanez C, Kasahara N, Gruber H, Pertschuk D, Jolly D, Robbins J, Ryken T, Agarwal S, Al-Keilani M, Alqudah M, Sibenaller Z, Assemolt M, Sai K, Li WY, Li WP, Chen ZP, Saito R, Sonoda Y, Kanamori M, Yamashita Y, Kumabe T, Tominaga T, Sarkar G, Curran G, Jenkins R, Scharnweber R, Kato Y, Lin J, Everson R, Soto H, Kruse C, Kasahara N, Liau L, Prins R, Semenkow S, Chu Q, Eberhart C, Sengupta R, Marassa J, Piwnica-Worms D, Rubin J, Serwer L, Kapp GT, Le Moan N, Yoshida Y, Romero JM, Ng S, Davis A, Ozawa T, Krtolica A, James CD, Cary SPL, Shai R, Pismenyuk T, Moshe I, Fisher T, Freedman S, Simon A, Amariglio N, Rechavi G, Toren A, Yalon M, Shen H, Decollogne S, Dilda P, Chung S, Luk P, Hogg P, McDonald K, Shimazu Y, Kurozumi K, Ichikawa T, Fujii K, Onishi M, Ishida J, Oka T, Watanabe M, Nasu Y, Kumon H, Date I, Sirianni RW, McCall RL, Spoor J, van der Kaaij M, Kloezeman J, Geurtjens M, Dirven C, Lamfers M, Leenstra S, Stephen Z, Veiseh O, Kievit F, Fang C, Leung M, Ellenbogen R, Silber J, Zhang M, Strohbehn G, Atsina KK, Patel T, Piepmeier J, Zhou J, Saltzman WM, Takahashi M, Valdes G, Inagaki A, Kamijima S, Hiraoka K, Micewicz E, McBride WH, Iwamoto KS, Gruber HE, Robbins JM, Jolly DJ, Kasahara N, Warren K, McCully C, Bacher J, Thomas T, Murphy R, Steffen-Smith E, McAllister R, Pastakia D, Widemann B, Wei K, Yang H, Huang C, Chen P, Hua M, Liu H, Woolf EC, Abdelwahab MG, Fenton KE, Liu Q, Turner G, Preul MC, Scheck AC, Yoshida Y, Ozawa T, Butowski N, Shen W, Brown D, Pedersen H, James D, Zhang J, Hariono S, Yao TW, Sidhu A, Hashizume R, James CD, Weiss WA, Nicolaides TP, Olusanya T. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY. Neuro Oncol 2013; 15:iii37-iii61. [PMCID: PMC3823891 DOI: 10.1093/neuonc/not176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
48
|
Lesniak M, Polanowska K, Seniów J. P 237. Repeated anodal tDCS coupled with cognitive training for patients with severe traumatic brain injury-a pilot RCT. Clin Neurophysiol 2013. [DOI: 10.1016/j.clinph.2013.04.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Rincon E, Kanojia D, Auffinger B, UIlya I, Han Y, Alemany R, Ramírez M, García-Castro J, Lesniak M. Therapeutic effect of mesenchymal stem cells in combination with oncolytic adenoviruses for the treatment of solid tumors in an immunocompetent mouse model (P2020). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.214.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Oncolytic adenoviruses (Ad) constitute a promising alternative for patients with solid tumors. Unfortunately, clinical trials have shown limited efficacy due to insufficient viral delivery to tumor and the ability of Ad to trigger antiviral immune response. We have previously documented enhanced Ad delivery in vivo using human mesenchymal stem cells (MSCs). However, a major limitation in the field is the lack of immune- and replication-competent models. In this study, we used syngeneic CMT64 cells as an immunocompetent model to analyze the antitumoral response followed by treatment with MSCs and oncolytic Ad ICOVIR5. First, we demonstrated that ICOVIR5 replicates and has cytopatic effect in CMT64 cells. To evaluate the in vivo efficacy of ICOVIR5 using MSCs as carriers, CMT64 cells were grown in mouse flanks. Once the tumors were established, mice were divided into 4 groups (n=5/group). Groups 1/2 were treated with saline and groups 3/4 with MSCs. Given the fact that mouse MSCs do not support the replication of human Ad, tumors were injected with saline (groups 1/2) or ICOVIR5 (groups 3/4) to mimic the carrier role of human MSCs. This therapy was performed weekly for 3 weeks and the tumor volumes were measured. A significant decrease in the tumor volume (p<0.05) was found in the group treated with MSCs and ICOVIR5. These results establish a potential permissive model to study immune mechanisms involved in the antitumoral effects of MSCs as carriers for oncolytic Ad.
Collapse
Affiliation(s)
- Esther Rincon
- 1The Brain Tumor Center, University of Chicago, Chicago, IL
- 2Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, Spain
| | - Deepak Kanojia
- 1The Brain Tumor Center, University of Chicago, Chicago, IL
| | | | - Ilya UIlya
- 1The Brain Tumor Center, University of Chicago, Chicago, IL
| | - Yu Han
- 1The Brain Tumor Center, University of Chicago, Chicago, IL
| | - Ramon Alemany
- 3Institut Català d'Oncologia, IDIBELL, Barcelona, Spain
| | | | | | - Maciej Lesniak
- 1The Brain Tumor Center, University of Chicago, Chicago, IL
| |
Collapse
|
50
|
Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Brawanski A, Sim H, Hu B, Pineda CA, Yoon SO, Viapiano MS, Rajappa P, Cobb WS, Huang Y, Lyden DC, Bromberg J, Greenfield JP, Li M, Mukasa A, Inda MDM, Zhang J, Chin L, Cavenee W, Furnari F, Zheng PP, van der Weiden M, van der Spek PJ, Vincent AJ, Kros JM, Fathallah-Shaykh HM, Saut O, Lagaert JB, Colin T, Fathallah-Shaykh HM, Araysi L, Tang Z, Duck KA, Ponnuru P, Neely EB, Connor JR, Esencay M, Gonzalez P, Gaziel A, Safraz Y, Mira H, Hernando E, Zagzag D, McDermott RA, Ulasov I, Kaverina N, Gabikian P, Lesniak M, Iranmahboob A, Haber M, Esencay M, Fatterpekar G, Raz E, Placantonakis D, Zagzag D, Eoli M, Rabascio C, Cuppini L, Anghileri E, Pellegatta S, Calleri A, Mancuso P, Porrati P, Bertolini F, Finocchiaro G, Seals DF, Burger KL, Gibo DM, Debinski W, Esencay M, Zagzag D, Tran NL, Tuncali S, Kloss J, Yang Z, Schumacher CA, Diegel C, Ross JT, Williams BO, Eschbacher JM, Loftus JC, Whiteman M, Dombovy-Johnson M, Vangellow A, Liu Y, Carson-Walter E, Walter KA, Liu Y, Carson-Walter E, Walter K, Cortes-Santiago N, Gabrusiewicz K, Liu D, Hossain MB, Gumin J, Fan X, Conrad C, Aldape K, Gilbert M, Raghunathan A, Yung WKA, Fueyo J, Gomez-Manzano C, Bae E, Huang P, Burgett M, Muller-Greven G, Kar N, Gladson CL, Engler JR, Robinson AE, Molinaro A, Phillips JJ, Zadeh G, Burrell K, Hill R, Piao Y, Liang J, Henry V, Holmes L, Sulman E, deGroot JF, Piao Y, Liang J, Henry V, Holmes L, de Groot JF, Rong W, Funato K, Georgala P, Shimizu F, Droms L, Tabar V, Parker JJ, Dionne KR, Massarwa R, Klaassen M, Foreman NK, Niswander L, Canoll P, Kleinschmidt-DeMasters BK, Waziri A. LAB-ANGIOGENESIS AND INVASION. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|